719 Panoramica delle azioni Shandong Xinhua Pharmaceutical Company Limited, attraverso le sue consociate, sviluppa, produce e vende prodotti farmaceutici sfusi, preparati e prodotti chimici nella Repubblica Popolare Cinese, nelle Americhe, in Europa e a livello internazionale. Maggiori dettagli
Premi Analisi del rischio Non sono stati rilevati rischi per 719 dai nostri controlli di rischio.
Vedi tutti gli assegni di rischio Catturate i vostri pensieri, i link e la narrativa aziendale
Shandong Xinhua Pharmaceutical Company Limited Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Shandong Xinhua Pharmaceutical Prezzi storici delle azioni Prezzo attuale dell'azione HK$5.99 Massimo di 52 settimane HK$8.05 Minimo di 52 settimane HK$4.80 Beta -0.018 Variazione di 1 mese 3.81% Variazione a 3 mesi -8.69% Variazione di 1 anno 6.21% Variazione a 3 anni 25.58% Variazione a 5 anni 52.81% Variazione dall'IPO 34.03%
Notizie e aggiornamenti recenti
Shandong Xinhua Pharmaceutical Company Limited to Report Fiscal Year 2024 Results on Mar 31, 2025 Dec 31
Shandong Xinhua Pharmaceutical Company Limited (SEHK:719) signed an equity acquisition intention agreement to acquire 75% stake in Novosana (Taicang) Bio Feed Co., Ltd. from Novosana (Europe) B.V. Dec 12
Shandong Xinhua Pharmaceutical Company Limited Announces Calcium Gluconate Injection Passing the Generics Consistency Evaluation Nov 05
Third quarter 2024 earnings released: EPS: CN¥0.11 (vs CN¥0.18 in 3Q 2023) Oct 30
Shandong Xinhua Pharmaceutical Company Limited Obtains FDA Approval of Abbreviated New Drug Application Oct 28
Investor sentiment improves as stock rises 16% Oct 02 Vedi altri aggiornamenti
Shandong Xinhua Pharmaceutical Company Limited to Report Fiscal Year 2024 Results on Mar 31, 2025 Dec 31
Shandong Xinhua Pharmaceutical Company Limited (SEHK:719) signed an equity acquisition intention agreement to acquire 75% stake in Novosana (Taicang) Bio Feed Co., Ltd. from Novosana (Europe) B.V. Dec 12
Shandong Xinhua Pharmaceutical Company Limited Announces Calcium Gluconate Injection Passing the Generics Consistency Evaluation Nov 05
Third quarter 2024 earnings released: EPS: CN¥0.11 (vs CN¥0.18 in 3Q 2023) Oct 30
Shandong Xinhua Pharmaceutical Company Limited Obtains FDA Approval of Abbreviated New Drug Application Oct 28
Investor sentiment improves as stock rises 16% Oct 02
Shandong Xinhua Pharmaceutical Company Limited to Report Q3, 2024 Results on Oct 30, 2024 Sep 30
Shandong Xinhua Pharmaceutical Company Limited Announces Interim Cash Dividend of the Year 2024 of A Shares, Payable on 27 September 2024 Sep 21
Shandong Xinhua Pharmaceutical Company Limited Receives Notification of Approval of Supplementary Drug Application Sep 13
Shandong Xinhua Pharmaceutical Company Limited Announces Esomeprazole Magnesium Obtains the Notification of Approval of Marketing Application for Chemical Substance Drugs Sep 02
Upcoming dividend of HK$0.027 per share Aug 28
Second quarter 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.17 in 2Q 2023) Aug 23
Shandong Xinhua Pharmaceutical Company Limited Announces Interim Dividend, Payable on or Before 27 September 2024 Aug 22
Shandong Xinhua Pharmaceutical Company Limited Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2023, Payable on 30 July 2024 Jul 24
Shandong Xinhua Pharmaceutical Company Limited to Report First Half, 2024 Results on Aug 23, 2024 Jun 29
Dividend of HK$0.27 announced Jun 28
Shandong Xinhua Pharmaceutical Company Limited Approves Final Cash Dividend for the Year Ended 31 December 2023, Payable on 30 July 2024 Jun 26
Shandong Xinhua Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2024 May 29
First quarter 2024 earnings released: EPS: CN¥0.21 (vs CN¥0.23 in 1Q 2023) Apr 26
Shandong Xinhua Pharmaceutical Company Limited to Report Q1, 2024 Results on Apr 26, 2024 Mar 30
Full year 2023 earnings released: EPS: CN¥0.74 (vs CN¥0.62 in FY 2022) Mar 29
Shandong Xinhua Pharmaceutical Company Limited Proposes Final Dividend for the Year Ended 31 December 2023 Mar 28
Shandong Xinhua Pharmaceutical Company Limited Receives Notification of Approval of Application for Marketing of Active Pharmaceutical Ingredient Feb 28
Now 22% overvalued Jan 25
Shandong Xinhua Pharmaceutical Company Limited Announces on Memantine Hydrochloride Tablets Obtaining the Drug Registration Certificate Jan 19
Shandong Xinhua Pharmaceutical Company Limited to Report Fiscal Year 2023 Results on Mar 29, 2024 Dec 30
Shandong Xinhua Pharmaceutical Company Limited Announces Executive Changes Dec 26
Shandong Xinhua Pharmaceutical Company Limited Receives Drug Registration Certificate of levamlodiping besylate tablets (2.5mg) Dec 15
Third quarter 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.15 in 3Q 2022) Oct 29
Shandong Xinhua Pharmaceutical Company Limited Announces Approval of Marketing Application for Chemical Raw Material Drugs for Drugsof Febuxostat Oct 11
Second quarter 2023 earnings released: EPS: CN¥0.17 (vs CN¥0.13 in 2Q 2022) Aug 25
Shandong Xinhua Pharmaceutical Company Limited Receives the Drug Registration Certificate of Alogliptin Benzoate Tablets Approved and Issued by the National Medical Products Administration Aug 12
Shandong Xinhua Pharmaceutical Company Limited Announces Resignation of Ling Peixue as Independent Non-Executive Director and Member of Strategic Development Committee and Remuneration and Examination Committee Jul 27
Shandong Xinhua Pharmaceutical Company Limited Announces Final Dividend on A Shares for the Year 2022, Payable on July 26, 2023 Jul 22
Shandong Xinhua Pharmaceutical Company Limited Announces Rabeprazole Sodium Enteric-coated Tablets (20mg) Passing the GenericsConsistency Evaluation Jul 15 Shandong Xinhua Pharmaceutical Company Limited Announces on New Drug Specifications and Passing the Generics Consistency Evaluation Jul 11
Upcoming dividend of HK$0.22 per share at 3.6% yield Jun 30
Shandong Xinhua Pharmaceutical Company Limited Obtains Alogliptin Benzoate Approval of Marketing Application for Chemical Raw Material Drugs Jun 21
Shandong Xinhua Pharmaceutical Company Limited Receives Notice of Approval of Supplementary Drug Application from the National Medical Products Administration Jun 14
Shandong Xinhua Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2023 May 25
Shandong Xinhua Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2023 May 24
Full year 2022 earnings released: EPS: CN¥0.62 (vs CN¥0.56 in FY 2021) Mar 27
Investor sentiment improves as stock rises 24% Feb 17
Investor sentiment deteriorated over the past week Dec 27
Investor sentiment improved over the past week Dec 06
Investor sentiment improved over the past week Nov 18
Less than half of directors are independent Nov 16
Investor sentiment improved over the past week Nov 09
Shandong Xinhua Pharmaceutical Company Limited Approves Board Appointments Oct 28
Third quarter 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.14 in 3Q 2021) Oct 27
Shandong Xinhua Pharmaceutical Company Limited to Report Q3, 2022 Results on Oct 25, 2022 Oct 13
Shandong Xinhua Pharmaceutical Company Limited Announces Board Changes Sep 20
Second quarter 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.16 in 2Q 2021) Aug 31
Shandong Xinhua Pharmaceutical Company Limited to Report First Half, 2022 Results on Aug 30, 2022 Aug 19
Shandong Xinhua Pharmaceutical Company Limited Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 05 August 2022 Jul 30
Investor sentiment deteriorated over the past week Jul 21
Upcoming dividend of HK$0.18 per share Jul 08
Shandong Xinhua Pharmaceutical Company Limited Announces Resignation of Du Deping as Executive Director and General Manager Jul 04
Shandong Xinhua Pharmaceutical Company Limited Approves Final Dividend for the Year Ended 31 December 2021, Payable on 5 August 2022 Jul 01
Shandong Xinhua Pharmaceutical Company Limited, Annual General Meeting, Jun 30, 2022 Jun 01
Investor sentiment improved over the past week May 28
Investor sentiment improved over the past week Apr 28
Less than half of directors are independent Apr 27
Shandong Xinhua Pharmaceutical Company Limited Proposes to Omit Final Cash Dividend for 2021 Apr 01
Full year 2021 earnings released: EPS: CN¥0.56 (vs CN¥0.52 in FY 2020) Apr 01
Now 21% undervalued after recent price drop Mar 16
Investor sentiment improved over the past week Dec 22
Third quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.12 in 3Q 2020) Oct 16
Second quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.14 in 2Q 2020) Aug 30
Shandong Xinhua Pharmaceutical Company Limited announced that it expects to receive CNY 249.999998 million in funding from Hualu Investment Development Co., Ltd. Apr 16
Full year 2020 earnings released: EPS CN¥0.52 (vs CN¥0.48 in FY 2019) Apr 01
Shandong Xinhua Pharmaceutical Company Limited to Report Fiscal Year 2020 Results on Mar 31, 2021 Feb 24
New 90-day high: HK$5.40 Feb 19
Investor sentiment improved over the past week Feb 04
New 90-day high: HK$3.88 Jan 20
Shandong Xinhua Pharmaceutical Company Limited Announces Board Appointments Dec 23
New 90-day low: HK$3.64 Dec 14
Shandong Xinhua Pharmaceutical Company Limited Announces Board Appointments Dec 02
Shandong Xinhua Pharmaceutical Company Limited Announces the Retirement of Certain Directors and Supervisors Nov 20
Third quarter earnings released Oct 23
Shandong Xinhua Pharmaceutical Company Limited to Report Nine Months, 2020 Results on Oct 22, 2020 Oct 13
New 90-day low: HK$3.86 Sep 24
New 90-day low - HK$3.97 Sep 08
Earnings released Aug 23
Shandong Xinhua Pharmaceutical Company Limited to Report First Half, 2020 Results on Aug 24, 2020 Aug 01
Shandong Xinhua Pharmaceutical Company Limited (SEHK:719) completed the acquisition of 33% stake in Shandong Xinhua Wanbo Chemical Industrial Co., Ltd from Hualu Holding Co., Ltd. Jul 31 Rendimenti per gli azionisti 719 HK Pharmaceuticals HK Mercato 7D 2.6% -4.0% -2.1% 1Y 6.2% -9.4% 16.9%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: 719 ha superato il Hong Kong Pharmaceuticals che ha restituito -9.4 % nell'ultimo anno.
Rendimento vs Mercato: 719 ha avuto una performance inferiore al mercato Hong Kong che ha registrato un rendimento 16.9 % nell'ultimo anno.
Volatilità dei prezzi Is 719's price volatile compared to industry and market? 719 volatility 719 Average Weekly Movement 9.3% Pharmaceuticals Industry Average Movement 6.2% Market Average Movement 8.1% 10% most volatile stocks in HK Market 16.1% 10% least volatile stocks in HK Market 3.7%
Prezzo delle azioni stabile: 719 non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.
Volatilità nel tempo: La volatilità settimanale ( 9% ) di 719 è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda Fondato I dipendenti AMMINISTRATORE DELEGATO Sito web 1943 7,064 Wenhui Xu www.xhzy.com
Shandong Xinhua Pharmaceutical Company Limited, attraverso le sue controllate, sviluppa, produce e vende prodotti farmaceutici sfusi, preparati e prodotti chimici nella Repubblica Popolare Cinese, nelle Americhe, in Europa e a livello internazionale. L'azienda offre farmaci antipiretici e analgesici, farmaci cardiovascolari e cerebrovascolari, farmaci antinfettivi, farmaci per il sistema nervoso centrale e neurologici e altri farmaci. L'azienda è impegnata nello sviluppo di attività immobiliari, nella gestione di immobili, nell'installazione di impianti elettrici e nella promozione e applicazione di servizi scientifici e tecnologici.
Mostra di più Shandong Xinhua Pharmaceutical Company Limited Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di Shandong Xinhua Pharmaceutical con la sua capitalizzazione di mercato? 719 statistiche fondamentali Capitalizzazione di mercato HK$9.84b Guadagni(TTM ) HK$476.73m Ricavi(TTM ) HK$8.86b
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) 719 Conto economico (TTM ) Ricavi CN¥8.34b Costo del fatturato CN¥6.32b Profitto lordo CN¥2.01b Altre spese CN¥1.56b Guadagni CN¥448.62m
Ultimi guadagni dichiarati
Sep 30, 2024
Prossima data di guadagno
Mar 31, 2025
Utile per azione (EPS) 0.66 Margine lordo 24.15% Margine di profitto netto 5.38% Rapporto debito/patrimonio netto 32.5%
Come si è comportato 719 nel lungo periodo?
Vedi performance storica e confronto Dividendi
0.9% Rendimento attuale del dividendo
42% Rapporto di remunerazione
Analisi aziendale e situazione dei dati finanziari Dati Ultimo aggiornamento (ora UTC) Analisi dell'azienda 2025/01/04 00:35 Prezzo dell'azione a fine giornata 2025/01/03 00:00 Guadagni 2024/09/30 Guadagni annuali 2023/12/31
Fonti dei dati I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC . I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
Pacchetto Dati Tempistica Esempio Fonte USA * Dati finanziari della società 10 anni Conto economico Rendiconto finanziario Bilancio Stime di consenso degli analisti +3 anni Previsioni finanziarie Obiettivi di prezzo degli analisti Prezzi di mercato 30 anni Prezzi delle azioni Dividendi, scissioni e azioni Proprietà 10 anni Top azionisti Insider trading Gestione 10 anni Team di leadership Consiglio di amministrazione Sviluppi principali 10 anni
* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui .
Modello di analisi e Snowflake I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github ; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube .
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .
Fonti analitiche Shandong Xinhua Pharmaceutical Company Limited è coperta da 3 analisti. 0 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
Analista Istituzione Alex Fan GF Securities (Hong Kong) Brokerage Limited Ming Li Industrial Securities Co. Ltd. Guohe Fan Phillip Securities (HK)
Mostra 0 altri analisti 
